Beger Procedure (Duodenum-Preserving Pancreatic Head Resection)

Indications and patient selection: 1) Indications - chronic pancreatitis with inflammatory pancreatic head mass causing intractable pain not responsive to medical therapy and endoscopic intervention; common bile duct or duodenal compression by pancreatic head mass; pancreatic ductal hypertension with dilated main duct in body/tail (often >5 mm); failed endotherapy (ERCP with stenting/dilation); 2) Patient characteristics - chronic pancreatitis (alcoholic, hereditary, autoimmune, idiopathic) with disabling pain, narcotic dependence, weight loss, recurrent admissions; quality of life severely impaired; 3) Anatomic considerations - inflammatory pancreatic head mass without confirmed malignancy (intraoperative or preoperative biopsy excludes neoplasia in most); 4) Contraindications - pancreatic head adenocarcinoma (Whipple preferred for oncologic clearance); pancreatic neuroendocrine tumor or IPMN with malignancy concern; severe portal hypertension or ascites; severe comorbidities; 5) Patient evaluation - cross-sectional imaging (CT/MRI/MRCP), ERCP/EUS to define ductal anatomy, biopsy to exclude malignancy in high-risk cases (significant elevation of CA 19-9, dominant mass), nutritional assessment, narcotic management plan; 6) Variants - Beger procedure (original): subtotal pancreatic head resection with preservation of duodenum and bile duct; Frey procedure: similar but with longitudinal pancreatojejunostomy of body/tail (better for diffuse main duct disease); Berne modification (modified Beger): no transection of pancreatic neck, simpler reconstruction.

Surgical technique: 1) Incision and exploration - bilateral subcostal or upper midline; assessment of pancreas, biliary system, splenic vessels; intraoperative biopsy to exclude malignancy; 2) Mobilization - Kocher maneuver to mobilize duodenum and pancreatic head; division of gastrocolic and gastrohepatic ligaments; entry into lesser sac; 3) Pancreatic neck transection - dissection of pancreatic neck off SMV/portal vein; transection of pancreatic neck preserving 5-10 mm rim of pancreatic tissue along duodenum; 4) Pancreatic head resection - subtotal removal of pancreatic head, leaving thin shell along duodenum and bile duct (preserving blood supply via gastroduodenal artery branches); ductal stump in remnant pancreatic body; 5) Bile duct considerations - preserve common bile duct unless fibrotically encased (then internal stenting or external drainage during resection); 6) Reconstruction - Roux-en-Y jejunal loop, end-to-side pancreaticojejunostomy with remnant pancreas (preserved tail), drainage of inflammatory cavity (saucerization of head remnant, jejunal patch); 7) Variations - Frey procedure adds longitudinal pancreatojejunostomy of body/tail for diffuse ductal involvement; Berne modification simplifies by avoiding pancreatic neck transection.

Outcomes and postoperative care: 1) Operative metrics - operative time 4-6 hours; blood loss 300-700 mL; transfusion 5-15%; mortality <2% in experienced centers; 2) Morbidity - overall 15-25%, lower than Whipple (35-50%); pancreatic fistula 5-10% (clinically relevant), bile leak 3-5%, delayed gastric emptying 5-15% (significantly less than Whipple), wound infection 5-10%, intra-abdominal collections 3-5%; 3) Length of stay 7-12 days vs Whipple 10-15 days; 4) Pain relief - 80-95% complete or substantial pain relief at 1 year, sustained at 5 years; superior to drainage procedures alone for inflammatory mass; comparable to Whipple but with lower morbidity; 5) Endocrine function - new onset diabetes 5-15% (less than Whipple 20-30%); existing diabetes worsening less common; 6) Exocrine function - exocrine insufficiency requiring enzyme replacement 25-50% at 5 years; better preserved than Whipple; 7) Narcotic dependence - significant reduction in 70-85%; requires multidisciplinary pain program for full benefit; 8) Quality of life - significantly improved compared to medical therapy alone, sustained improvement over years; 9) Long-term outcomes - 10-year survival similar to general population (with same risk factors); recurrence of symptoms in 10-20% requiring further intervention; 10) Postoperative care - clear liquids day 1-2, advancing as tolerated; pain management with multimodal regimen, taper narcotics aggressively; nutritional support; pancreatic enzyme supplementation if exocrine insufficiency; close followup for diabetes screening; long-term tobacco/alcohol cessation; 11) Comparative outcomes vs Whipple - meta-analyses show equivalent pain relief, lower morbidity, shorter hospital stay, better quality of life, preserved gastric emptying, lower diabetes incidence; Beger preferred for benign inflammatory head mass.